Loading clinical trials...

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Phase Ib, IIa Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Chemotherapy-Naive Stage IV Non-Small Cell Lung Cancer

NCT01004731•University of Alabama at Birmingham

View on ClinicalTrials.gov

Summary

The objective is to evaluate the toxicity profile, response rate, and time to progression of Cetuximab administered in combination with either Carboplatin + Gemcitabine in patients with advanced non-small cell lung cancer with positive EGFr expression.

Detailed Description

The primary objective of this study is to evaluate the safety profile of Cetuximab when used in combination with gemcitabine and carboplatin in patients with EGFr positive, chemotherapy-naive, stage IV non-small cell lung cancer (NSCLC). Also, the study will determine the response rate in patients with EGFr positive chemotherapy-naive, stage IV non-small cell lung cancer (NSCLC) treated with Cetuximab in combination with gemcitabine and carboplatin as well as determine the time to progression in patients with EGFr positive chemotherapy-naive, stage IV NSCLC treated with Cetuximab in combination with gemcitabine and carboplatin.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a diagnosis of histologically/cytologically confirmed advanced non- small cell lung cancer (NSCLC).
•Have uni-dimensionally measurable and/or evaluable advanced NSCLC.
•Have Stage IV or recurrent disease following radiation therapy.
•Have ECOG performance status of 0-1 or Karnofsky performance status of 80- 100 at study entry.
•Have given signed informed consent.
•Be at least 18 years of age.
•Have ANC greater than or equal to 1,500/mm3, platelets greater than or equal to 100,000/mm3, WBC greater than or equal to 3,000 mm3, and hemoglobin greater than or equal to 9 g/dL.
•Have total bilirubin less than or equal to 1.5 x upper limits of normal, Alk Phos, AST and ALT less than or equal to 2.5 x upper limits of normal.
•Have serum creatinine less than or equal to 1.5 mg/dL, or calculated creatinine clearance greater than or equal to 60 cc/minute.
•Be disease free from a previously treated malignancy for more than three years. Patients with a history or a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix will not be excluded.
+2 more criteria

Exclusion Criteria

•Have received prior murine monoclonal antibody or Cetuximab therapy.
•Have disease amenable to curative surgery.
•Have received prior chemotherapy.
•Have received radiation therapy within 3 weeks prior to the first infusion of Cetuximab.
•Have a history of clinically significant cardiac disease, serious arrhythmias, or significant conduction abnormalities, in the judgment of the PI.
•Have uncontrolled seizure disorder, active neurological disease, or Grade 2 or higher neuropathy.
•Be pregnant or breast-feeding.
•Have received any investigational agent(s) within 1 month of study entry.

Locations (1)

University of Alabama at Birmingham

Birmingham, Alabama, United States

Key Dates

Start Date

June 1, 2001

Primary Completion Date

January 1, 2002

Completion Date

January 1, 2006

Last Updated

May 25, 2023

Enrollment

ACTUAL participants

Conditions

Stage IV Non-Small Cell Lung Cancer

Interventions

Cetuximab in combination with Carboplatin/Gemcitabine

DRUG

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

NCT02495896

Head and Neck Squamous Cell CarcinomaMetastatic Pancreatic Adenocarcinoma+14 more

View study

ACTIVE_NOT_RECRUITING

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

NCT04056247

Stage IV Non-small Cell Lung CancerStage IV Malignant Melanoma+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 25, 2023Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Inclusion Criteria

Exclusion Criteria

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

CISH Inactivated TILs in the Treatment of NSCLC

Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer

Collection of Blood Samples in Patients With Non-small Cell Lung Cancer